Compare FedEx Corporation (FDX) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Eli Lilly And Co — how do they compare? FedEx Corporation trades at $291.66 (market cap $69.04B), while Eli Lilly And Co trades at $1,178.99 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 15.1× FedEx Corporation's market cap, and FedEx Corporation pays the higher dividend (1.67%). Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Eli Lilly And Co for 93 Days on average.
| FDX | LLY | |
|---|---|---|
Market Cap | $69.04B | $1.04T |
Volume | 1,287,367 | 3,064,878 |
Sector | Industrials | Health |
52-Week High | $339.35 | $1.28K |
52-Week Low | $180.87 | $799.57 |
Typical Hold Time | 87 Days | 93 Days |
Enterprise Value | $98.68B | $1.09T |
Dividend Yield | 1.67% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FDX trades at $290.98, up 0.67% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $6.31 exceeding the $5.96 estimate. Revenue for 2025 was $87.93 billion, with a net income margin of 4.68%. Recent news includes a $300 million order for electric trucks from Harbinger and shareholder approval of executive compensation.
The outlook is mixed: analyst consensus is bullish with a $307.55 price target, but rising fuel costs and geopolitical tensions pose near-term risks. Earnings growth and cost-cutting initiatives support upside, while margin pressure from higher diesel prices and competitive pressures are key concerns for investors.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
